Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross NC Testosterone Cypionate Coverage Upda…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Testosterone Cypionate (Azmiro) - Notification

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical necessity and prior authorization notification criteria for Azmiro (testosterone cypionate IM) administered by a healthcare professional for testosterone replacement and select indications; applies to Blue Cross NC membership.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyTestosterone Cypionate (Azmiro) - Notification
    Policy CodePolicy N/A
    Change TypeMaterial coverage updates
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of diagnosis, two early-morning testosterone labs, symptoms, and trial/failure or intolerance to Depo-Testosterone.
    SourceLink
    POLICY UPDATE CHANGES

    Requirement for use of a self-administered formulation of testosterone unless certain criteria are met.

    Requirement for trial and failure of testosterone cypionate (Depo-Testosterone).

    Requirement that the patient will not be treated for age-related or late-onset hypogonadism.

    Added maximum units and Site of Care medical necessity criteria.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    365duration (approval)
    J1072HCPCS
    10,400max units
    50–400 mgFDA dosing

    Coverage Criteria

    Documentation Required

    Laboratory documentation required

    Provider must document laboratory testing before initiation and for continuation of therapy. Two early morning (AM) pretreatment testosterone levels drawn on separate days are required for patients not currently receiving testosterone replacement therapy; alternatively, patients already receiving therapy must have at least one total or free testosterone level checked within the past year. Medical record documentation of test results must be submitted with the request. If laboratory proof is not provided, the request may be denied.

    • Two pretreatment early morning testosterone levels, drawn on subsequent days, with results showing either: total testosterone below the laboratory lower limit of normal or < 300 ng/dL, OR free testosterone below the laboratory lower limit of normal (medical record documentation required).
    • If patient is currently receiving testosterone therapy: documentation of a total or free testosterone level checked within the past year (medical record documentation required).
    • Consequences: Requests lacking required laboratory documentation may be denied or returned for additional information.

    Initial Therapy

    Initial Therapy — Covered when ALL of the following are met:

    ALL of the following

    • ALL of the following

      • ANY of the following

        • The patient is NOT currently receiving testosterone replacement therapy and has TWO pretreatment early morning testosterone levels, drawn on subsequent days, meeting one of: total serum testosterone below the laboratory lower limit of normal OR < 300 ng/dL; OR free serum testosterone below the laboratory lower limit of normal (medical record documentation required).
        • The patient is currently receiving testosterone replacement therapy and has had a total or free serum testosterone level checked in the past year (medical record documentation required).
    • Presence of symptoms of hypogonadism at the time of diagnosis, including at least ONE of: incomplete or delayed sexual development; decreased libido; decreased spontaneous erections; breast discomfort/gynecomastia; loss of axillary and/or pubic hair; very small (< 5 mL) or shrinking testes; infertility due to low sperm count; height loss due to vertebral fractures/low bone density; hot flushes or sweats.
    • The patient has a physical or cognitive limitation that makes self-administration unsafe or not feasible, demonstrated by BOTH: inability to self-administer; AND lack of caregiver/support for assistance (medical record documentation required).

    ALL of the following

    • For indications other than primary hypogonadism (e.g., HIV-related hypogonadism, delayed puberty, gender dysphoria, or palliative treatment of metastatic inoperable breast cancer) specific additional criteria in the policy must be met (medical record documentation required).

    ALL of the following

    • Duration of approval: 365 days (1 year).

    Continuation Therapy

    Continuation Therapy — Covered for continuation when ALL of the following are met:

    ALL of the following

    • The patient was previously approved through Blue Cross NC initial criteria for approval; OR would have met initial criteria at therapy start; AND
    • The patient has demonstrated a positive clinical response while using the medication; AND
    • ANY of the following

      • The patient has a diagnosis of hypogonadism and has had a total serum or free serum testosterone level checked in the past year (medical record documentation required).
      • The patient is using the agent for palliative treatment of metastatic inoperable breast cancer.

    Initial Therapy

    inv-17: Initial Therapy

    Initial approval requirements

    Diagnosis and lab confirmation: Established diagnosis of hypogonadism with androgen deficiency AND diagnostic confirmation by TWO pretreatment early morning testosterone levels on subsequent days (total < lab LLN or <300 ng/dL) or low free testosterone OR patient is currently on therapy with a total or free testosterone checked in the past year2 morning levels or recent labs

    Medical record documentation required

    Symptom requirement: Presence of at least ONE listed symptom of hypogonadism at time of diagnosis>=1 symptom

    See policy symptom list

    Special indications: Alternate covered uses include HIV with unexplained weight loss or low BMD and low testosterone; delayed puberty; palliative metastatic breast cancer; or gender dysphoria meeting specified criteria

    Continuation Therapy

    inv-18: Continuation Therapy

    Continuation approval requirements

    Continuation nodes: Patient previously approved or would have met initial criteria; has demonstrated positive clinical response; has ongoing lab monitoring (total or free testosterone in past year); continued non-age-related indication; self-administration limitation and prior product trial/intolerance requirements apply

    Duration of approval: 365 days

    Provider Actions & Documentation

    Prior Authorization

    Prior authorization/notification required for J1072 (Azmiro)

    Prior authorization/notification is required for HCPCS J1072 (testosterone cypionate, Azmiro). Documentation must include diagnosis, required laboratory results, symptom documentation, and other criteria per the policy.

    • Submit prior authorization/notification for J1072 (testosterone cypionate, intramuscular injection).
    • Include diagnosis, qualifying labs, symptom documentation, and any required additional clinical records.
    Step Therapy

    Document trial and inadequate response to Depo-Testosterone (or intolerance/contraindication)

    Policy requires a trial and documented inadequate response to testosterone cypionate (Depo-Testosterone) before approval, unless there is documented intolerance, FDA-labeled contraindication, or hypersensitivity to Depo-Testosterone.

    • Document trial and inadequate response to Depo-Testosterone in the medical record.

    Coding

    Covered HCPCS CodesHCPCSCovered
    J1072testosterone cypionate, intramuscular injection
    inv-07: Total serum testosterone threshold
    Threshold valueTotal serum testosterone < 300 ng/dL or below the testing laboratory's lower limit of normal
    Alternative lab criterionFree serum testosterone below the laboratory lower limit of normal (accepted alternative)
    Specimen timingTwo pretreatment early morning testosterone levels drawn on subsequent days required for diagnostic confirmation

    Step Therapy / Prior Treatment Requirements

    StepRequirementDocumentation required
    1Trial of testosterone cypionate (Depo-Testosterone) with documented inadequate response required prior to approval of the requested productMedical record documentation of trial and inadequate response to Depo-Testosterone
    1Alternatively, documented intolerance, FDA-labeled contraindication, or hypersensitivity to testosterone cypionate (Depo-Testosterone) may substitute for trialMedical record documentation of intolerance, FDA contraindication, or hypersensitivity to Depo-Testosterone
    —If patient has physical or cognitive limitation and lacks caregiver support, self-administration requirement may be waivedMedical record documentation demonstrating inability to self-administer AND lack of caregiver/support

    Quantity Limits

    inv-20: testosterone cypionate (Azmiro) — maximum units allowed
    Maximum units allowed10,400 units per duration of approval
    Duration tied to limitMaximum units apply for the duration of approval (365 days)
    HCPCS code referenceAssociated HCPCS code J1072 (testosterone cypionate, intramuscular injection)

    Site of Care Medical Necessity

    inv-03: Site of Care Medical Necessity

    Site of Care conditions

    Inpatient administration: Injection/infusion may be given in an inpatient setting if the medical necessity criteria are met AND the inpatient admission is NOT for the sole purpose of administering the injection/infusion
    Outpatient hospital administration: Injection/infusion may be given in an outpatient hospital setting if medical necessity criteria are met AND ONE of: history of severe adverse event to the medication; conditions that increase risk for severe adverse event (e.g., unstable renal, cardiopulmonary conditions, unstable vascular access); history of mild adverse events not managed with mild pre-medication; inability to physically/cognitively adhere to regimen; new to therapy (<3 months) or re-initiation per definitions; or requirement to change formulation

    If Site of Care criteria are not met, administration should occur in office or home (with or without supervision by a certified healthcare professional)

    Note

    Background

    Azmiro (testosterone cypionate, intramuscular) is indicated for testosterone replacement in males with deficiency or absence of endogenous testosterone, including primary hypogonadism, hypogonadotropic hypogonadism, and selected use to stimulate puberty in carefully selected males with delayed puberty. It is also indicated for palliative treatment of metastatic mammary cancer in postmenopausal women. The labeling specifies that safety and efficacy have not been established for men with age-related (late-onset) hypogonadism and for pediatric patients below 12 years, and the policy’s clinical requirements and exclusions reflect those limitations.

    Definitions

    inv-15: Primary hypogonadism — definition and examples
    DefinitionPrimary hypogonadism: testicular failure (congenital or acquired) causing deficiency or absence of endogenous testosterone
    Common causes/examplesCryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy
    Other causesKlinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals
    inv-16: Hypogonadotropic hypogonadism — definition
    DefinitionHypogonadotropic hypogonadism: congenital or acquired deficiency of gonadotropin production due to pituitary-hypothalamic injury or idiopathic causes
    Etiologies notedIdiopathic gonadotropin deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation

    Revision History

    2026-07-01Policy effective dateLatest

    Policy became effective and instituted multiple material changes: requirement for use of a self‑administered testosterone formulation unless documented inability, requirement for trial and inadequate response to Depo‑Testosterone (testosterone cypionate), exclusion of treatment for age‑related/late‑onset hypogonadism, and addition of maximum units and Site of Care medical necessity criteria.

    2026-04-02Notification

    Policy notification issued to stakeholders advising of upcoming policy effective date and changes on 2026-07-01.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyTestosterone Cypionate (Azmiro) - Notification
    Policy CodePolicy N/A
    Change TypeMaterial coverage updates
    Effective DateJul 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization with documentation of diagnosis, two early-morning testosterone labs, symptoms, and trial/failure or intolerance to Depo-Testosterone.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation TherapyProvider Actions & DocumentationCodingStep Therapy / Prior Treatment RequirementsQuantity LimitsSite of Care Medical NecessityBackgroundDefinitionsRevision History
  1. ONE of the following: the patient has tried and had an inadequate response to testosterone cypionate (Depo-Testosterone) (medical record documentation required); OR the patient has an intolerance, FDA-labeled contraindication, or hypersensitivity to testosterone cypionate (Depo-Testosterone) (medical record documentation required).
  2. Requested quantity does NOT exceed the maximum units allowed for the duration of approval.
  3. The patient will NOT be treated for age-related or late-onset hypogonadism.
  4. The patient has a diagnosis of delayed puberty.
  5. The patient has a diagnosis of gender dysphoria and meets the policy's sex trait modification coverage criteria (medical record documentation required).
  6. The patient will NOT be treated for age-related or late-onset hypogonadism; AND
  7. The patient has a physical or cognitive limitation preventing safe use of a self-administered formulation, demonstrated by BOTH inability to self-administer AND lack of caregiver/support (medical record documentation required).
  8. ANY of the following

    • The patient has tried and had an inadequate response to testosterone cypionate (Depo-Testosterone) (medical record documentation required).
    • The patient has an intolerance, FDA-labeled contraindication, or hypersensitivity to testosterone cypionate (Depo-Testosterone) (medical record documentation required).
  9. Requested quantity does NOT exceed the maximum units allowed for the duration of approval.
  10. Duration of approval: 365 days (1 year).
  11. ALL of the following

    • For requests for injection or infusion administration in inpatient or outpatient hospital settings, Site of Care Criteria applies as outlined in the policy.

    Gender dysphoria requires coverage for sex trait modification, age and mental health/consent requirements

    Self-administration and trial requirements: Patient must use self-administered formulation unless unable to do so AND lacks caregiver support; patient must have tried and had inadequate response to Depo-Testosterone OR have intolerance/contraindication/hypersensitivity to Depo-Testosterone

    Medical record documentation required

    Quantity and duration: Requested quantity must not exceed maximum units (10,400) and duration of approval is 365 daysMax units 10,400; duration 365 days

    See dosing and maximum units

  12. Alternatively, document intolerance, FDA contraindication, or hypersensitivity to Depo-Testosterone.
  13. Documentation Required

    Baseline labs and symptom documentation required

    Medical record must document either two pretreatment early morning total testosterone levels on subsequent days meeting qualifying low thresholds (total < lab LLN or <300 ng/dL) or a low free testosterone level, and presence of at least one symptom of hypogonadism.

    • Two pretreatment early-morning testosterone measurements on subsequent days are required (total or free).
    • At least one hypogonadism symptom must be documented at diagnosis (e.g., decreased libido, decreased spontaneous erections, loss of body hair).
    Documentation Required

    Additional clinical documentation: self‑administration limitation and product trial records

    Document inability to self-administer (physical or cognitive limitation) and lack of caregiver support when claiming exemption from the self-administration requirement; also document trials, failures, or intolerance to alternatives such as Depo-Testosterone when applicable.

    • Record both inability to self-administer and absence of caregiver/support to qualify for clinician-administered product.
    • Provide medical record evidence of trial/failure or intolerance/contraindication to Depo-Testosterone if relying on that criterion.
    Denial Risk

    Age-related (late-onset) hypogonadism is excluded — risk of denial

    Requests for treatment of age-related or late-onset hypogonadism are excluded and will not meet criteria; submitting such requests risks denial.

    • Do not request therapy for age-related (late-onset) hypogonadism under this policy; such requests will not meet criteria.
    • Continuation approvals explicitly require that the patient will NOT be treated for age-related or late-onset hypogonadism.

    Site-of-care rules: inpatient restricted; outpatient hospital only with qualifying criteria

    Injection/infusion administration may be given inpatient only if medical necessity criteria are met and the inpatient admission is not solely for administration; outpatient hospital administration is allowed only when medical necessity criteria are met and at least one specified condition applies — otherwise administration should occur in the office or home.

    • Inpatient: Admission may not be solely for the purpose of administering the injection/infusion.
    • Outpatient hospital: Allowed only if medical necessity criteria are met AND one qualifying condition applies (e.g., history of severe adverse event, increased risk for severe event, inability to adhere, new to therapy, re-initiation, formulation change).
    • If Site of Care criteria are not met, administer in home or physician office.
    Clinical contextListed as a covered indication for testosterone replacement when associated with testosterone deficiency